디지털 당뇨병 관리 시장 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Digital Diabetes Management Market was valued at USD 20.2 billion in 2025 and is estimated to grow at a CAGR of 13.3% to reach USD 69.1 billion by 2035.

Market growth is driven by a major shift in diabetes care delivery from intermittent clinical consultations toward continuous, technology-enabled monitoring supported by integrated digital ecosystems. Rising prevalence of diabetes, fueled by aging populations, sedentary lifestyles, and increasing obesity rates, is significantly expanding the patient base worldwide. At the same time, healthcare systems are facing a widening gap between patient demand and endocrinology workforce availability, which is accelerating the adoption of digital self-management tools. In several developing regions, limited access to specialist care is further increasing reliance on remote monitoring platforms and telehealth-enabled solutions. Growing healthcare expenditure related to diabetes is also contributing to the expansion of the addressable market for digital care technologies. Over the past few years, awareness and adoption of continuous glucose monitoring, connected insulin delivery systems, and integrated digital health platforms have increased substantially. This trend is supported by stronger clinical guidelines, expanding reimbursement frameworks, and increasing evidence demonstrating improved patient outcomes through digital intervention. Overall, the market is evolving rapidly as healthcare shifts toward connected, preventive, and data-driven diabetes management models.

The continuous glucose monitoring systems segment accounted for 53.4% share in 2025 and is projected to grow at a CAGR of 13.3% through 2035. This category remains the central pillar of the market due to its ability to provide real-time glucose tracking and continuous metabolic insights. Unlike traditional monitoring methods that offer intermittent readings, these systems deliver continuous data streams that support predictive alerts, pattern recognition, and improved insulin dosing decisions. Their clinical effectiveness in improving glycemic control and reducing complications continues to drive strong adoption across patient populations.

The hospitals segment generated 62.9% of the global digital diabetes management market revenue in 2025 and are projected to register a CAGR of 13.7% through the forecast period, representing the fastest-growing end-use segment. Growth is primarily supported by increasing investments in continuous glucose monitoring (CGM)-enabled inpatient care, wider implementation of automated insulin delivery (AID) technologies within specialized diabetes treatment departments, and growing adoption of enterprise-level data management platforms for clinical analytics, patient population monitoring, and reporting functions. The use of CGM systems in hospital environments has gained significant momentum as clinical studies continue to demonstrate improved glucose management outcomes across inpatient care settings.

North America Digital Diabetes Management Market accounted for 33.4% share in 2025 and is projected to grow at a CAGR of 13.1% through 2035. The region remains the most advanced and commercially developed market, supported by strong healthcare infrastructure, high adoption of digital health technologies, and favorable reimbursement frameworks. Canada is also experiencing steady growth, with expanding public healthcare coverage for advanced glucose monitoring solutions across major provinces. The region's market is further strengthened by widespread availability of integrated insulin delivery and monitoring systems, supported by leading regulatory approvals and strong clinical adoption.

Key companies operating in the Global Digital Diabetes Management Market include Dexcom, Inc., Medtronic Plc, Insulet Corporation, Abbott Laboratories, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, Glooko Inc., Senseonics, DarioHealth Corporation, Emperra GmbH E-Health Technologies, Ypsomed Holding, and Pendiq. Companies in the digital diabetes management market are focusing on strengthening their position through continuous technological innovation, ecosystem integration, and expansion of connected care platforms. A major strategy involves developing advanced continuous glucose monitoring systems and automated insulin delivery solutions with improved accuracy, real-time analytics, and predictive capabilities. Firms are increasingly investing in artificial intelligence and cloud-based platforms to enable seamless data sharing between patients and healthcare providers. Strategic partnerships with hospitals, insurers, and telehealth providers are helping expand adoption and improve reimbursement access. Companies are also focusing on interoperability between devices and software platforms to enhance user experience and clinical efficiency. Geographic expansion into emerging markets is being prioritized to capture growing patient populations with limited access to specialist care.

Table of Contents

Chapter 1. Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust
• 1.10 Market definitions

Chapter 2. Executive Summary

• 2.1 Industry synopsis, 2022 - 2035
  • 2.1.1 Business trends
  • 2.1.2 Product trends
  • 2.1.3 Patient Type trends
  • 2.1.4 End use trends
  • 2.1.5 Regional trends

Chapter 3. Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising number of people suffering from diabetes.
    • 3.2.1.2 Rising healthcare expenditure towards diabetes.
    • 3.2.1.3 Growing awareness about technologically advanced products.
    • 3.2.1.4 Favorable reimbursement policies.
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Rising number of product launches.
    • 3.2.2.2 High cost of advanced devices.
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration of AI and data analytics in diabetes management
    • 3.2.3.2 Expansion of remote patient monitoring (RPM) and telehealth
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing trend analysis (Driven by primary research)
• 3.7 Future market trends
• 3.8 Patent analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis
• 3.11 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.12 Value chain analysis (Driven by primary research)
• 3.13 Investment & funding analysis (Driven by primary research)
• 3.14 Consumer insights (Driven by primary research)

Chapter 4. Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis, by region, 2025
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
  • 4.2.4 Middle East & Africa
  • 4.2.5 Latin America
• 4.3 Key developments
  • 4.3.1 Key partnerships & collaborations
  • 4.3.2 Major M&A activities
  • 4.3.3 Product innovations & launches
  • 4.3.4 Market expansion strategies
• 4.4 Competitive positioning matrix

Chapter 5. Market Size and Forecast, By Product, 2022 - 2035 (USD Million)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 By Device Type
    • 5.2.1.1 Smart blood glucose meters
    • 5.2.1.2 CGM
    • 5.2.1.3 Smart insulin pumps & patches
    • 5.2.1.4 Smart insulin pens
  • 5.2.2 By portability
    • 5.2.2.1 Handheld
    • 5.2.2.2 Wearable
• 5.3 Services
  • 5.3.1 Telemedicine & virtual consultation services
  • 5.3.2 Remote monitoring services
  • 5.3.3 Diabetes education, coaching & support services
• 5.4 Software and Apps
  • 5.4.1 Digital diabetes management apps
  • 5.4.2 Data management software & platforms

Chapter 6. Market Size and Forecast, By Patient type, 2022 - 2035 (USD Million)

• 6.1 Key trends
• 6.2 Type 1
• 6.3 Type 2

Chapter 7. Market Size and Forecast, By End Use, 2022 - 2035 (USD Million)

• 7.1 Key trends
• 7.2 Hospital
• 7.3 Home settings
• 7.4 Diagnostic centers & clinics
• 7.5 Other end users

Chapter 8. Market Size and Forecast, By Region, 2022 - 2035 (USD Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Netherlands
  • 8.3.5 Spain
  • 8.3.6 Italy
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 India
  • 8.4.5 Australia
• 8.5 Middle East & Africa
  • 8.5.1 Saudi Arabia
  • 8.5.2 UAE
  • 8.5.3 South Africa
• 8.6 Latin America
  • 8.6.1 Brazil
  • 8.6.2 Argentina
  • 8.6.3 Mexico

Chapter 9. Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Ascensia Diabetes Care Holdings AG
• 9.3 DarioHealth Corporation
• 9.4 Dexcom, Inc.
• 9.5 Emperra GmbH E-Health Technologies
• 9.6 F. Hoffmann-La Roche Ltd
• 9.7 Glooko Inc.
• 9.8 Insulet Corporation
• 9.9 Medtronic Plc
• 9.10 Novo Nordisk A/S
• 9.11 Pendiq
• 9.12 Senseonics
• 9.13 Tandem Diabetes Care, Inc.
• 9.14 Tidepool
• 9.15 Ypsomed Holding